<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9008">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05707208</url>
  </required_header>
  <id_info>
    <org_study_id>ST-CP-202</org_study_id>
    <nct_id>NCT05707208</nct_id>
  </id_info>
  <brief_title>A Randomized, Controlled Study of Repeat Dose Sustained Release Lidocaine for Treatment of Chronic Scrotal Pain</brief_title>
  <official_title>A Randomized, Controlled Phase II Study of Repeat Dose ST-01 (Lidocaine Polymer Solution) vs Lidocaine for Spermatic Cord Block in Men With Chronic Scrotal Content Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sustained Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sustained Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multi-center, phase 2, randomized, single-blind, three-arm, active-controlled study is&#xD;
      comparing repeat doses, every 28 days, of standard of care (SOC) plus ST-01 against SOC plus&#xD;
      1% lidocaine HCL in men experiencing chronic scrotal content pain (CSCP). The main purpose of&#xD;
      this study is to determine if repeat injections of ST-01 are safe and effective in reducing&#xD;
      pain. After completing a screening phase participants will be randomized into one of three&#xD;
      groups: 1) ST-01 70 mg/mL arm, 2) ST-01 140 mg/mL arm, 3) 1% Lidocaine HCL arm (Control).&#xD;
      Participants will receive up to 4 study treatment injections at 28-day intervals.&#xD;
      Participants randomized to the Control arm will be given the opportunity to cross over to an&#xD;
      ST-01 treatment arm after 2 study treatments.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 21, 2023</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Single blind. Participant will not know what study arm they have been randomized to.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Pain Scores on the Numerical Rating Scale (NRS) at 56 days.</measure>
    <time_frame>28 days after the second injection of ST-01 or 56 days after the first injection if only one study injection is received.</time_frame>
    <description>To evaluate the change of pain score from baseline to day 56 in the active treatment cohorts (after 1 or 2 injections of ST-01) and compare to the standard of care control group. Pain score being used is the participant reported NRS scale (measured from 0-10 where 0 is no pain and 10 is maximum pain.)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">63</enrollment>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>ST-01 70 mg/mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ST-01 140 mg/mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1% Lidocaine HCL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ST-01</intervention_name>
    <description>A sustained release lidocaine formulation designed for the treatment of acute and chronic pain.</description>
    <arm_group_label>ST-01 140 mg/mL</arm_group_label>
    <arm_group_label>ST-01 70 mg/mL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1% Lidocaine HCL</intervention_name>
    <description>Currently approved lidocaine</description>
    <arm_group_label>1% Lidocaine HCL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult (≥ 19 years) male&#xD;
&#xD;
          2. Unilateral or bilateral scrotal pain lasting &gt; 3 months&#xD;
&#xD;
          3. Have nociceptive scrotal pain&#xD;
&#xD;
          4. Average daily maximum scrotal pain score over 7 days ≥ 4 on the 0-10 NRS (Appendix 2).&#xD;
             Participants with bilateral scrotal pain must be able to distinguish one side with&#xD;
             pain score ≥ 4 and the opposite side must have a maximum scrotal pain score of ≤ 3.0&#xD;
             at baseline.&#xD;
&#xD;
          5. Positive response to test spermatic cord block with 1% lidocaine (Lidocaine&#xD;
             Hydrochloride Injection, USP, 1%, 10 mg/mL), defined as a decrease in pain score of at&#xD;
             least 2 within 1 hour of injection&#xD;
&#xD;
          6. Baseline blood levels without clinically significant abnormalities including liver&#xD;
             function tests (alanine aminotransferase [ALT], aspartate aminotransferase [AST],&#xD;
             gamma-glutamyl transferase [GGT], and alkaline phosphatase [ALP]) no greater than 50%&#xD;
             above the upper limit of normal&#xD;
&#xD;
          7. If sexually active, is willing to use adequate birth control methods to prevent&#xD;
             pregnancy over the course of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Negative response to test spermatic cord block, defined as absence of a decrease in&#xD;
             pain score of at least 2 within an hour of injection&#xD;
&#xD;
          2. Other pain generator site with NRS pain score ≥ 4&#xD;
&#xD;
          3. History of allergic reaction to lidocaine or any component of ST-01&#xD;
&#xD;
          4. Any contraindication to local anesthesia with lidocaine (e.g., known hypersensitivity&#xD;
             to anesthetics of the amide type; hypokalemia, complete heart block, anticoagulants&#xD;
             (aspirin permitted), antiarrhythmic medication.)&#xD;
&#xD;
          5. Active infection involving the urinary tract or scrotum&#xD;
&#xD;
          6. Inability to give consent&#xD;
&#xD;
          7. Inability to follow up according to the protocol&#xD;
&#xD;
          8. Negative response to previous spermatic cord block&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Graeme Boniface, PhD.</last_name>
    <role>Study Director</role>
    <affiliation>Sustained Therapeutics Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lesley Parker</last_name>
    <phone>(604) 875-5594</phone>
    <email>lparker@sustainedtx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Graeme Boniface</last_name>
    <phone>(604) 875-5594</phone>
    <email>gboniface@prostatecentre.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vancouver Prostate Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ST-CP-202 Study Clinical Trials Coordinator</last_name>
      <phone>604-875-4111</phone>
      <phone_ext>67898</phone_ext>
      <email>clinic@ubcurology.com</email>
    </contact>
    <investigator>
      <last_name>Ryan Flannigan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Men's Health Clinic Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3P 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Landon - Clinical Trial Coordinator</last_name>
      <phone>204-221-4476</phone>
      <email>info@mhclinic.ca</email>
    </contact>
    <investigator>
      <last_name>Premal Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>January 20, 2023</study_first_submitted>
  <study_first_submitted_qc>January 27, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2023</study_first_posted>
  <last_update_submitted>April 6, 2023</last_update_submitted>
  <last_update_submitted_qc>April 6, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Scrotal Content Pain</keyword>
  <keyword>Chronic testicular pain</keyword>
  <keyword>Chronic scrotal pain</keyword>
  <keyword>Orchialgia</keyword>
  <keyword>spermatic cord</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

